Biofrontera Reports Q1 Revenue Miss Despite 17% Growth, Narrows EBITDA Loss
BFRI sits 86% above its 52-week low of $0.536 on elevated volume (3.1× avg).
Summary
Biofrontera reported Q1 revenue of $10.10 million, a 17% increase year-over-year driven by higher Ameluz sales and price increases, but missed analyst consensus estimates of $10.25 million. The company also narrowed its adjusted EBITDA loss and saw gross margin expand significantly to 80% from 62%. However, it continued to report a net loss of $4.80 million. This earnings report follows the company's recent 10-K filing which raised substantial doubt about its ability to continue as a going concern and noted a Nasdaq delisting notice. While revenue growth and improved gross margins are positive operational signs, the revenue miss and ongoing net losses are critical for a company facing a going concern warning. Traders will be evaluating whether these results provide a clear path towards sustained profitability and cash-flow breakeven, which the company remains focused on. Investors will monitor future financial reports for consistent progress towards profitability and cash-flow positivity, as well as any updates regarding the Nasdaq listing status and potential equity financing.
At the time of this announcement, BFRI was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $0.54 to $1.19. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.